<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140850</url>
  </required_header>
  <id_info>
    <org_study_id>82001568</org_study_id>
    <nct_id>NCT05140850</nct_id>
  </id_info>
  <brief_title>Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in oPRES</brief_title>
  <official_title>Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in Obstetrics Posterior Reversible Encephalopathy Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dunjin Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the long-term consequences of neuroimaging and&#xD;
      perceived cognitive dysfunction in obstetrics posterior reversible encephalopathy syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study. The investigators divided the PE or E patients into two groups,&#xD;
      namely PRES group and non-PRES group, according to diagnostic criteria . The general&#xD;
      information（demographic data，blood pressure.etc.）and blood sample will be collected.&#xD;
      Additionally,all patients receive neuroimaging examination（DTI,ASL,3D-TMI.etc.）and&#xD;
      neuro-cognitive test（MMSE,MOCA,CFQ, etc.） to assess the cerebral white matter lesions and&#xD;
      cognitive changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>neuroimaging examination</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>the degree of white matter lesions(0,normal; 1, limited cortical or subcortical white matter oedema; 2, white matter oedema &gt; cortical oedema, white matter oedema extending into deep white matter; 3, white matter oedema &gt; cortex oedema, oedema extending to the ventricular surface; 4, the involved regions substantially extend to the ventricular surface and are almost completely conﬂuent; 5, involved regions are fully conﬂuent and continuous, ventricular deformity due to the oedema).The value of fractional anisotropy(FA) in PRES group may higher than non- PRES group, and mean diffusivity (MD) in PRES group may lower than non- PRES group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neuro-cognitive test of Mini-mental State Examination</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>the scores of Mini-mental State Examination,normal (27-30);mild (21-26); moderate (10-20); severe (0-9).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neuro-cognitive test of Montreal Cognitive Assessment</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>the scores of Montreal Cognitive Assessment,normal (≥26); abnormal (&lt;26).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>Hypertension: blood pressure ≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of lactate dehydrogenase(LDH)</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>inflammatory: LDH&gt;380U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of LDL in blood</measure>
    <time_frame>within 10 years after deliver</time_frame>
    <description>hyperlipidemia：LDL&gt;3.12mmol/L</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neuroimaging</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Posterior Reversible Encephalopathy Syndrome</condition>
  <arm_group>
    <arm_group_label>PRES group</arm_group_label>
    <description>PE or E with PRES</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-PRES group</arm_group_label>
    <description>PE or E without PRES</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>neuroimaging examination,neuro-cognitive test,blood pressure,blood sample</intervention_name>
    <description>neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested</description>
    <arm_group_label>PRES group</arm_group_label>
    <arm_group_label>non-PRES group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We divided the PE or E patients into two groups, namely PRES group and non-PRES group,&#xD;
        according to diagnostic criteria . the general information（demographic data，blood&#xD;
        pressure.etc.）and blood sample will be collected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients were diagnosed of PE or E&#xD;
&#xD;
          2. patients received cranial image examination&#xD;
&#xD;
          3. patients consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients combined other neurological diseases&#xD;
&#xD;
          2. patients combined mental illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dunjin Chen</last_name>
    <phone>18928916722</phone>
    <email>gzdrchen@gzhmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Dunjin Chen</investigator_full_name>
    <investigator_title>Director of obstetrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Posterior Leukoencephalopathy Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

